Skip to content

Advertisement

Open Access

Neutralizing anti-Tat antibodies prolonged HAART interruption in vaccines in a prospective structured interruption study

  • Nathan Clumeck1,
  • Philippe Hermans1,
  • Daniel Zagury2,
  • Hélène Le Buanec2,
  • Arsène Burny3,
  • Bernard Bizzini2,
  • Bruce Gilliam4,
  • Robert Redfield4 and
  • Robert Gallo4
Retrovirology20063(Suppl 1):S15

https://doi.org/10.1186/1742-4690-3-S1-S15

Published: 21 December 2006

Keywords

PlaceboInfectious DiseaseCancer ResearchCell ApoptosisEpidemiological Data

Anti-Tat therapeutic vaccination has been clinically investigated by different groups [14], given that 1) extracellular Tat protein induces T cell apoptosis and cellular immune suppression, 2) epidemiological data showed that LTNP exhibit high level of serum anti-Tat Ab, negatively correlated with p24 antigenemia, 3) in Tat immunized macaques, viremia decreased following SHIV challenge. Anti-Tat therapeutic vaccination using Tat Toxoid adjuvanted either with Seppic [1, 2] or with alum or DcChol (Aventis Pasteur) proved to be safe. A prospective structured treatment interruption study (STI) monitored according to EU guidelines was conducted at Hospital St-Pierre, Brussels (Pr. N. Clumeck) on 31 vaccinees who received a DcChol adjuvanted Tat Toxoid (n = 12), a DcChol placebo (n = 8) or non adjuvanted Tat toxoid (n = 11). The 2 year study follow-up showed that vaccinees developing high titer of Abs neutralizing Tat bioactivity prolonged HAART-interruption.

Authors’ Affiliations

(1)
Division of Infectious Diseases, CHU Saint-Pierre, Brussels, Belgium
(2)
Neovacs, S.A., Paris, France
(3)
Laboratory of Experimental Hematology, Bordet Institute, Brussels, Belgium
(4)
Institute of Human Virology, University of Maryland Biotechnology Center, Baltimore, USA

References

  1. Gringeri A, Santagostino E, Muca-Perja M, Mannucci PM, Zagury JF, Bizzini B, Lachgar A, Carcagno M, Rappaport J, Criscuolo M, Blattner W, Burny A, Gallo RC, Zagury D: Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients. J Hum Virol. 1988, 1: 293-298.Google Scholar
  2. Gringeri A, Santagostino E, Muca-Perja M, Le Buanec H, Bizzini B, Lachgar A, Zagury JF, Rappaport J, Burny A, Gallo RC, Zagury D: Tat toxoid as a component of a preventive vaccine in seronegative subjects. J Acquir Immune Defic Syndr Hum Retrovirol. 1999, 20: 371-375.View ArticlePubMedGoogle Scholar
  3. Caputo A, Gavioli R, Ensoli B: Recent advances in the development of HIV-1 Tat-based vaccines. Curr HIV Res. 2004, 2: 357-376. 10.2174/1570162043350986.View ArticlePubMedGoogle Scholar
  4. Calarota SA, Leandersson AC, Bratt G, Hinkula J, Klinman DM, Weinhold KJ, Sandstrom E, Wahren B: Immune responses in asymptomatic HIV-1-infected patients after HIV-DNA immunization followed by highly active antiretroviral treatment. J Immunol. 1999, 163: 2330-2338.PubMedGoogle Scholar

Copyright

© Clumeck et al; licensee BioMed Central Ltd. 2006

This article is published under license to BioMed Central Ltd.

Advertisement